Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer - Wikidata - wikimedia - TriplyDB

Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer

Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer

http://www.wikidata.org/entity/Q33621256

about

Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma Betulinic acid in complex with a gamma-cyclodextrin derivative decreases proliferation and in vivo tumor development of non-metastatic and metastatic B164A5 cells.Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β2-adrenergic receptor activation.Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer.Pancreatic Cancer: Progress in Systemic Therapy.Unique cellular interactions between pancreatic cancer cells and the omentum Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.Loss of MTSS1 results in increased metastatic potential in pancreatic cancer.Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma.Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216.S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.Antitumor activity of amidino-substituted benzimidazole and benzimidazo[1,2-a]quinoline derivatives tested in 2D and 3D cell culture systems.Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction.Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions Pancreatic Cancer Chemoresistance to Gemcitabine.Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL.Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery.Vascular beds maintain pancreatic tumour explants for ex vivo drug screening.Development and in-vitro characterization of nanoemulsions loaded with paclitaxel/γ-tocotrienol lipid conjugates.Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma.Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo.

P2860

Q24627664-05922CB6-3B33-459F-BB96-4F31705D1FCE Q33755743-E8172137-D346-41BD-8B70-7E99E7212DD8 Q34403588-C5F6BEF4-5118-4A79-A03E-8283BABE6905 Q35556561-E923E562-537B-465D-9B92-C6A9F5D04CAF Q35565766-4E3A2124-FCC7-4F3A-BD86-D971A953DAFD Q35754482-805A7561-835D-468C-A674-3ED481FC072E Q36214623-883925FA-0300-4293-8ED1-5A8CBEF75F5D Q36232057-99C19BE1-D837-4AC4-9B81-DDD332EEB4EE Q36344551-74A66B0C-0351-4B09-BB7C-F6BCE9F4FED4 Q36410426-76E7DE9A-0D8D-4708-8519-FF18D6D8EC74 Q37565014-0D499ADC-86D4-4F41-A3A8-8FD966BEE89C Q37725460-0D475538-DC6A-4AFE-A69C-EDFBCA76CCAF Q37738158-2588CB32-9A2A-42B0-B4C5-B2134EC6BCCA Q38254746-753FA046-8C54-4EE7-9417-13CB617BA9D5 Q38546598-1330B430-2FC9-437B-9746-26BE5CAFED26 Q38689014-5D9FC621-A3A2-4C37-8D63-C4998DF96E7C Q38749227-8EB9A40E-3C8F-467F-A689-6D293B6F67AE Q38776511-C9B8AF3E-46F7-4D77-AF37-38ADF07A22EE Q38824533-5558E750-9F4C-4181-BCC9-8752B59D711A Q39008822-331D169B-49AC-40CC-98AC-514ACD36AC18 Q41598068-8DE888AE-5173-4BB8-B76D-3D6A7F6B4888 Q41608480-AB4380D5-0228-4DE2-9B5F-C29CB5AC9967 Q47135556-726F3822-8DD8-4F5A-BECA-65E5764BEABD Q47300891-787F0BE5-039A-4D61-84BE-A2F822604702 Q47301657-7C7151AF-A40A-45AF-B6EA-182AA6909453 Q48346642-D25FECFD-6D23-4E3D-A053-4426D62D17BB Q49359448-3708CD5A-20AF-4BB9-8662-E857F8478E41 Q49466133-76E8FE2B-462B-43E8-8894-93153958C2F4 Q49586874-94C50425-AABA-426C-B3D0-84DED69A9977 Q52592855-818F99F1-AEC1-4465-897E-5CFB57A5C8DA

P2860

Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer

http://www.wikidata.org/entity/Q33621256

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Comparative benefits of Nab-pa ...... experimental pancreatic cancer

@ast

Comparative benefits of Nab-pa ...... experimental pancreatic cancer

@en

type

label

Comparative benefits of Nab-pa ...... experimental pancreatic cancer

@ast

Comparative benefits of Nab-pa ...... experimental pancreatic cancer

@en

prefLabel

Comparative benefits of Nab-pa ...... experimental pancreatic cancer

@ast

Comparative benefits of Nab-pa ...... experimental pancreatic cancer

@en

P1433

Q33621256-38C0BCAF-F81B-48C5-A537-A417726E8828

P1476

Q33621256-110E458D-4DD2-40A2-BBFD-7F4AEF484A02

P2093

Q33621256-0A3EBA55-D313-471E-AC0D-0530A03FD2F3

Q33621256-3C912179-2D68-410B-AD7A-09EF2E3FAA6F

Q33621256-553C8785-E256-41BC-A303-32E908FAAB6D

Q33621256-579E9300-2BA8-412E-9BFF-49EADFCBAF86

Q33621256-72E776DB-4305-42B9-89A7-58729B133B30

Q33621256-7B9720D5-EF5D-4A76-A97F-6C6AEEDF7A8F

Q33621256-F7D6C56B-0A17-4608-A162-9EE7E8B4FD8D

P2860

Q33621256-0004EA73-9844-4A9C-A55E-890DD96FB894

Q33621256-04A570FE-90C7-42C3-8C16-986F6C58895B

Q33621256-04C3F183-C824-439B-B848-1F41B7DEE44C

Q33621256-10B0A452-17F4-4F92-A9FA-6617F3DF3004

Q33621256-138C1A9C-B9EF-41C3-999D-07D737E673A7

Q33621256-15F7EC2E-585D-4B0C-B334-DE7E5CA0C83B

Q33621256-245EF2B0-C880-4A3C-9CFC-740CB3F3DD3F

Q33621256-27A3F261-020C-4F73-9D9E-79D611C5B2D1

Q33621256-299E5A4B-AD5F-4DF3-BD78-D266C08E086E

Q33621256-2CE6A52C-5E67-4908-8503-ADA3603C7FE8

P304

Q33621256-E8DA0A75-3EC6-48B6-8C3E-6D3266230359

P31

Q33621256-AFA6ED4D-CA58-4264-85D9-A55C4ABE7377

P356

Q33621256-253B2E6D-D24C-4832-B6FE-C271654A6CF0

P407

Q33621256-27F6B3D5-4FF8-4242-A9E4-7CD602943813

P433

Q33621256-763B4113-127F-462E-901D-1CDCEA07D1D6

P478

Q33621256-55AF2D53-4313-4D75-B7F3-D0993E774009

P50

Q33621256-1CC7FCC8-9762-4FCB-9796-ABCA8BC1F6B9

P577

Q33621256-300FC058-EC2F-434D-AF86-EFBCA14865F6

P5875

Q33621256-D61219C6-8820-44E6-980B-6BDFD33F9B1B

P698

Q33621256-439A8258-A516-495B-B772-4AB1E02AC2B7

P932

Q33621256-44779426-F504-437D-B5B8-57BC11588932

P356

P1433

P1476

Comparative benefits of Nab-pa ...... experimental pancreatic cancer

@en

P2093

Anna M Schwarz

http://www.w3.org/2001/XMLSchema#string

Changguang Wang

http://www.w3.org/2001/XMLSchema#string

Changhua Zhang

http://www.w3.org/2001/XMLSchema#string

Margaret A Schwarz

http://www.w3.org/2001/XMLSchema#string

Niranjan Awasthi

http://www.w3.org/2001/XMLSchema#string

Noelle S Williams

http://www.w3.org/2001/XMLSchema#string

Roderich E Schwarz

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Docetaxel for treatment of solid tumours: a systematic review of clinical data.

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer.

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

P304

2361-2369

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CARCIN/BGT227

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

242333014

http://www.w3.org/2001/XMLSchema#string

P698

23803690

http://www.w3.org/2001/XMLSchema#string

P932

4023322

http://www.w3.org/2001/XMLSchema#string